Scientists have created new experimental drugs that work on three different fat-control systems in the liver instead of just one. In early tests with mice and human liver cells, the most promising compound reduced blood triglycerides and activated genes that burn fat more efficiently. These findings suggest a potential new approach to treating high cholesterol, though human testing is years away.
Scientists have created new experimental drugs based on a class of medications called fibrates that treat high cholesterol. According to Gram Research analysis, these new compounds work differently than current drugs by targeting three separate control systems in the liver that manage how the body processes fats. In early tests with mice and human liver cells, the most promising compounds reduced triglycerides (a type of blood fat) and activated genes that help the body burn fat more efficiently. While these are very early findings, the research suggests a new approach to treating metabolic disorders could eventually help millions of people with high cholesterol and related conditions.
Key Statistics
A 2026 research article published in the European Journal of Medicinal Chemistry found that new quinoline-based compounds activated two fat-regulating receptors (PPARα and FXR) while blocking a third (LXRα) in laboratory cell studies.
When the experimental compound 6d was given to mice on a high-fat diet, it decreased plasma triglyceride levels and promoted expression of genes responsible for fat breakdown in the liver, according to 2026 research from the European Journal of Medicinal Chemistry.
Halogen-substituted versions of the new compounds showed improved pharmacokinetic properties, meaning they were absorbed and metabolized more efficiently in the body compared to non-halogenated versions, according to preliminary 2026 research.
The Quick Take
- What they studied: Whether new experimental drugs based on fibrates could work better by targeting multiple control systems in the liver that regulate fat metabolism
- Who participated: Laboratory studies using mice fed high-fat diets and human liver cells grown in special 3D structures called spheroids. No human clinical trials were conducted
- Key finding: Two experimental compounds (called 6d and 6e) successfully activated two fat-regulating receptors while blocking a third, and when given to mice, compound 6d reduced blood triglycerides and activated genes that burn fat
- What it means for you: These findings are very early stage and only in animals and lab cells. If further development succeeds, these drugs might eventually offer better cholesterol control than current fibrates, but this is years away from human use
The Research Details
Researchers created new versions of fibrate drugs by adding quinoline and quinoxaline chemical structures to the original fibrate backbone. They tested these new compounds in laboratory dishes with human cells to see which ones activated or blocked three specific fat-regulating proteins called PPARα, FXR, and LXRα. The most promising compounds were then tested in mice that were fed a high-fat diet to see if they actually worked in a living body. Finally, they tested the compounds in human liver cells grown in 3D structures to confirm the effects would likely work in humans.
This approach is called a multitarget strategy because instead of hitting just one control system, the new drugs target three different ones. The researchers reasoned that by activating two systems and blocking a third, they could create a more powerful effect on how the body handles fats.
Current fibrate drugs only activate one receptor (PPARα), which limits how well they work. By targeting multiple receptors simultaneously, these new compounds could potentially lower cholesterol and triglycerides more effectively. This research approach matters because it shows how scientists can redesign old drugs to work better by understanding the multiple control systems involved in fat metabolism
This is early-stage research published in a respected chemistry journal. The studies progressed logically from laboratory cells to animal models to human cells, which is the proper sequence. However, no human trials have been conducted, and the sample sizes for animal studies were not specified. The work is preliminary and would need extensive additional testing before any drug could be considered for human use
What the Results Show
Among the new compounds tested, two quinoline derivatives (labeled 6d and 6e) showed the desired triple action: they activated PPARα and FXR while blocking LXRα. When compound 6d was given to mice eating a high-fat diet, it successfully reduced the amount of triglycerides in their blood. The drug also turned on genes in the liver that are responsible for breaking down fatty acids through a process called beta-oxidation, which is how the body burns fat for energy.
These results suggest the compounds work as intended in a living organism, not just in laboratory dishes. The fact that the drug activated fat-burning genes is particularly important because it shows the drug is engaging the right biological pathways. When tested in human liver cells grown in 3D structures, the compounds showed similar effects, suggesting they would likely work similarly in human livers.
The researchers also found that adding certain halogen atoms (like fluorine or chlorine) to the chemical structure improved the drug’s properties. These halogenated versions appeared to have better absorption and metabolism in the body, meaning they stayed active longer and worked more efficiently. The compounds showed good pharmacokinetic properties, which is scientific language for how well the drug moves through the body
Traditional fibrates like fenofibrate have been used for decades to lower triglycerides, but they only work through one pathway (PPARα activation). This research builds on that foundation by creating drugs that work through multiple pathways simultaneously. Previous research suggested that combining PPARα activation with FXR activation while blocking LXRα could create synergistic effects, meaning the combined action would be stronger than any single action alone. This study provides the first evidence that such compounds can be successfully created and do show metabolic benefits
This research only tested compounds in mice and human cells in laboratory conditions, not in living humans. The sample sizes for animal studies were not reported, making it difficult to assess statistical reliability. The study is very early stage, and many compounds that work in mice fail to work or prove unsafe in humans. The researchers did not test whether the compounds cause any side effects or toxicity. Long-term effects are unknown. This work represents a proof-of-concept that needs years of additional development before human trials could begin
The Bottom Line
These findings are too early to recommend any action for patients. Current fibrate medications remain the standard treatment for high triglycerides and should be used as prescribed by doctors. This research may eventually lead to better medications, but that is likely years away. People with high cholesterol should continue following their doctor’s advice regarding current medications, diet, and exercise
People with high triglycerides or dyslipidemia (abnormal blood fat levels) should be aware of this research as it may eventually lead to better treatment options. Pharmaceutical researchers and cardiologists should follow this work closely. People currently taking fibrates do not need to change their treatment based on this preliminary research
If these compounds continue to show promise, the typical development timeline would be 5 to 10 years before human clinical trials could begin, and another 5 to 10 years of testing before potential FDA approval. Realistic expectation for availability to patients is 10 to 20 years away, assuming successful development
Frequently Asked Questions
Can I take these new drugs for high cholesterol now?
No, these compounds are still in early laboratory and animal testing stages. They have not been tested in humans and are not available as medications. Current fibrate drugs remain the standard treatment for high triglycerides. Consult your doctor about appropriate options for your cholesterol levels
How do these new drugs work differently than current fibrates?
Current fibrates only activate one fat-control receptor (PPARα), while these new compounds activate two receptors (PPARα and FXR) while blocking a third (LXRα). This triple action may create stronger effects on fat metabolism, though this remains unproven in humans
When will these drugs be available to patients?
If development continues successfully, these compounds would need 5 to 10 years of additional testing before human trials could begin, followed by another 5 to 10 years of clinical testing. Realistic availability to patients is 10 to 20 years away, if approved
Are these drugs safe for humans?
Safety in humans is unknown. These compounds have only been tested in mice and human cells in laboratory conditions. Extensive safety testing in humans would be required before any approval. Many compounds that work in animals prove unsafe or ineffective in people
Should I stop taking my current cholesterol medication?
No, continue taking your current medications as prescribed by your doctor. This research is very early stage and does not affect current treatment recommendations. Stopping medication without medical guidance could increase your health risks
Want to Apply This Research?
- Users with high triglycerides could track their current triglyceride levels (from blood tests), dietary fat intake, and exercise minutes weekly. This establishes a baseline for comparison if new medications become available
- While waiting for potential new treatments, users could use the app to monitor and improve modifiable risk factors: reducing saturated fat intake, increasing aerobic exercise to 150 minutes weekly, and tracking weight loss progress
- Set quarterly reminders to log triglyceride levels from doctor visits. Track trends over time. Use the app to maintain consistent exercise and dietary habits that support heart health, which will benefit users regardless of which medications they take
This article describes early-stage research in laboratory animals and human cells. These compounds are not approved for human use and are not available as medications. This research does not represent medical advice or a change in treatment recommendations. People with high cholesterol or triglycerides should continue following their doctor’s treatment plan and not make any changes based on this preliminary research. Always consult with a healthcare provider before making decisions about cholesterol medications or treatment strategies. The findings described are preliminary and may not translate to human benefit.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.